Cyclooxygenase 2: A molecular target for cancer prevention and treatment

Trends in Pharmacological Sciences

Volumn 24, Issue 2, 2003, Pages 96-102

  Subbaramaiah, Kotha ^a   Dannenberg, Andrew J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; PACLITAXEL;

ADENOMATOUS POLYP; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; LUNG NON SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG DELIVERY SYSTEMS; HUMANS; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0037307483     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(02)00043-3     Document Type: Review

References (66)

1. Thun M.J., et al. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 94:2002;252-266.
2. Oshima M., et al. Suppression of intestinal polyposis in APCΔ716 knockout mice by inhibition of cyclooxygenase-2 (Cox-2). Cell. 87:1996;803-809.
3. Chulada P.C., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res. 60:2000;4705-4708.
4. Tiano H.F., et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62:2002;3395-3401.
5. Jacoby R.F., et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the Min mouse model of adenomatous polyposis. Cancer Res. 60:2000;5040-5044.
6. Oshima M., et al. Chemoprevention of intestinal polyposis in ApcΔ716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res. 61:2001;1733-1740.
7. Harris R.E., et al. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res. 60:2000;2101-2103.
8. Fischer S.M., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinog. 25:1999;231-240.
9. Steinbach G., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in Familial Adenomatous Polyposis. New Engl. J. Med. 342:2000;1946-1952.
10. Silverstein F.E., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. J. Am. Med. Assoc. 284:2000;1247-1255.
11. FitzGerald G.A., Patrono C. The COXIBS, selective inhibitors of cyclooxygenase-2. New Engl. J. Med. 345:2001;433-442.
12. Smith W.L., et al. Cyclooxygenases: structural, cellular and molecular biology. Annu. Rev. Biochem. 69:2000;145-182.
13. Subbaramaiah K., et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 56:1996;4424-4429.
14. Wadleigh D.J., et al. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW 264.7 macrophages. J. Biol. Chem. 275:2000;6259-6266.
15. Kurumbail R.G., et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature. 384:1996;644-648.
16. Dannenberg A.J., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2:2001;544-551.
17. Shao J., et al. Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells. J. Biol. Chem. 275:2000;33951-33956.
18. Dixon D.A., et al. Post-transcriptional control of cyclooxygenase-2 gene expression. J. Biol. Chem. 275:2000;11750-11757.
19. Subbaramaiah K., et al. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. J. Biol. Chem. 277:2002;18649-18657.
20. Subbaramaiah K., et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2. J. Biol. Chem. 275:2000;14838-14845.
21. Zhang F., et al. Dihydroxy bile acids activate the transcription of cyclooxygenase-2. J. Biol. Chem. 273:1998;2424-2428.
22. Subbaramaiah K., et al. Retinoids and carnosol suppress cyclooxygenase-2 transcription by CREB-binding protein/p300-dependent and -independent mechanisms. Cancer Res. 62:2002;2522-2530.
23. Subbaramaiah K., et al. Inhibition of cyclooxygenase-2 gene expression by p53. J. Biol. Chem. 274:1999;10911-10915.
24. Leung W.K., et al. Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer. Br. J. Cancer. 84:2001;335-339.
25. Ristimaki A., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 62:2002;632-635.
26. Song S.H., et al. Transcriptional silencing of cyclooxygenase-2 by hyper-methylation of the 5′ CpG island in human gastric carcinoma cells. Cancer Res. 61:2001;4628-4635.
27. Cok S.J., Morrison A.R. The 3′-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J. Biol. Chem. 276:2001;23179-23185.
28. Sheng H., et al. Transforming growth factor-β1 enhances Ha-ras-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J. Biol. Chem. 275:2000;6628-6635.
29. Zhang Z., et al. Posttranscriptional regulation of cyclooxygenase-2 in rat intestinal epithelial cells. Neoplasia. 2:2000;523-530.
30. Dixon D.A., et al. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J. Clin. Invest. 108:2001;1657-1665.
31. Liu C.H., et al. Over-expression of cyclooxygenase (Cox)-2 is sufficient to induce tumorigenesis in transgenic mice. J. Biol. Chem. 276:2001;18563-18569.
32. Neufang G., et al. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc. Natl. Acad. Sci. U. S. A. 98:2001;7629-7634.
33. Kawamori T., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58:1998;409-412.
34. Fischer S.M., et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol. Carcinog. 25:1999;231-240.
35. Rioux N., Castonguay A. Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res. 58:1998;5354-5360.
36. Grubbs C.J., et al. Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res. 60:2000;5599-5602.
37. Shiotani H., et al. Increased expression of cyclooxygenase-2 protein and 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res. 61:2001;1451-1456.
38. Buttar N.S., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology. 122:2002;1101-1112.
39. Williams C.S., et al. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60:2000;6045-6051.
40. Nishimura G., et al. A selective cyclooxygenase-2 inhibitor suppresses tumor growth in nude mouse xenografted with human head and neck squamous carcinoma cells. Jpn. J. Cancer Res. 90:1999;1152-1162.
41. Stolina M., et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:2000;361-370.
42. Masferrer J.L., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60:2000;1306-1311.
43. Tomozawa S., et al. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. Br. J. Cancer. 81:1999;1274-1279.
44. Milas L., et al. Enhancement of tumor response to γ-radiation by an inhibitor of cyclooxygenase-2 enzyme. J. Natl. Cancer Inst. 91:1999;1501-1504.
45. Mann M., et al. Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology. 120:2001;1713-1719.
46. Hida T., et al. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase-2 inhibitor, JTE-522, and conventional anticancer agents. Clin. Cancer Res. 8:2002;2443-2447.
47. Ferrario A., et al. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res. 62:2002;3956-3961.
48. Gupta R.A., DuBois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer. 1:2001;11-21.
49. Patel V.A., et al. Regulation of MDR-1 (P-glycoprotein) by cyclooxygenase-2. J. Biol. Chem. 277:2002;38915-38920.
50. 2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology. 137:1996;5739-5742.
51. Brueggemeier R.W., et al. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett. 140:1999;27-35.
52. Ratnasinghe D., et al. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res. 21:2001;2141-2147.
53. Steinauer K.K., et al. Radiation induces upregulation of cyclooxygenase-2 (COX-2). protein in PC-3 cells. Int. J. Radiat. Oncol. Biol. Phys. 48:2000;325-328.
54. Langman M.J., et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. J. Am. Med. Assoc. 282:1999;1929-1933.
55. Phillips R.K.S., et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 50:2002;857-860.
56. Jacoby R.F., et al. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 60:2000;1864-1870.
57. Blanke C.D., et al. A phase II trial of celecoxib, irinotecan, 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;505.
58. Lin E.H., et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and improved time to tumor progression in metastatic colorectal cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 21:2002;2364.
59. Altorki N.K., et al. Celecoxib (Celebrex), a selective COX-2 inhibitor, enhances the response to preoperative paclitaxel/carboplatin in early stage non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 21:2002;101.
60. Csiki I., et al. Cyclooxygenase-2 (COX-2) inhibition+docetaxel in recurrent non-small cell lung cancer: preliminary results of a phase II trial. Proc. Am. Soc. Clin. Oncol. 21:2002;1187.
61. Subbaramaiah K., et al. Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. J. Biol. Chem. 276:2001;12440-12448.
62. Trifan O.C., et al. Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11. Cancer Res. 62:2002;5778-5784.
63. Hwang D.H., et al. National Cancer Institute workshop on chemopreventive properties of nonsteroidal anti-inflammatory drugs: role of COX-dependent and independent mechanisms. Neoplasia. 4:2002;91-97.
64. Zhang X., et al. Malignant transformation and antineoplastic actions of nonsteroidal antiinflammatory drugs (NSAIDs) on cyclooxygenase-null embryo fibroblasts. J. Exp. Med. 190:1999;451-459.
65. Mukherjee D., et al. Risk of cardiovascular events associated with selective COX-2 inhibitors. J. Am. Med. Assoc. 286:2001;954-959.
66. White W.B., et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or dicofenac. Am. J. Cardiol. 89:2002;425-430.